The emergence of compounds like copyright and Semaglutide signifies a major shift in how we approach blood sugar. These groundbreaking therapies belong to a class known as GLP-1 target agonists, which replicate the effects of a natural hormone that manages glucose levels and hunger. Initially, developed for diabetic conditions, their effectiveness